Use when targeting Hepatology or deciding whether a liver-biology or liver-disease study fits this venue. Encodes the journal's fit, the AASLD clinical-and-basic/translational evidence bar, reporting-guideline and registration requirements, AASLD/Wiley house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice.
SkillScore74Maintained
Automatic
◆Writing & Editing pack
Last verified 9/1/2026
What it changes
Passed 17 of 23 test cases with the skill, and 5 of 23 without it.
Without skill22%
With skill74%
Checks it passed that the model alone missed
Fit rating is Low
Output contains exact key [Top risk]
Output uses exact bracketed label [Fit]
and 14 more in the full report
12 fixed5 passed either way6 still failing0 broke
Pass-rate lift
+52 pp
Tokens
+35%
Agent turns
0%
Response time
-40%
Model gemini-3.6-flashMeasured 9/1/2026v117 of 23 cases passed with skill
Tokens, turns and time describe resource use, not a dollar price.
See it in action
One of 12 test cases the skill fixed. Same model, same prompt, with and without the skill.
1 of 12
Prompt
Our paper analyzes treatment response in European patients with primary biliary cholangitis based explicitly on European Association for the Study of the Liver clinical practice guidelines, targeting a predominantly European hepatology audience. We want an evaluation of where to send this paper. Please provide your fit review using standard bracketed categories.
case-07 · gemini-3.6-flash · 9/1/2026 · answers are capped and redacted
What's inside
The instructions your model reads when the skill loads.
SKILL.md85 linessingle file
Hepatology (hepatology)
Journal positioning
Hepatology is the flagship journal of the American Association for the Study of Liver Diseases (AASLD), publishing original research spanning liver biology and disease — from molecular and cellular hepatobiliary science through translational and clinical studies in viral, metabolic (MASLD/MASH), alcohol-related, autoimmune and cholestatic liver disease, cirrhosis and portal hypertension, liver cancer, and transplantation. It serves a North-American-anchored but international hepatology and hepatobiliary-science readership and the AASLD practice-guideline community, with a notable strength in mechanistic and basic/translational liver biology alongside practice-relevant clinical research. Confirmatory or descriptive work without a clear mechanistic or clinical advance, and studies with weak biological grounding, are a poor fit. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live Hepatology author instructions.
When to trigger
The author names Hepatology for a basic, translational, or clinical liver study and wants a fit/framing check.
A liver study must be re-framed around a mechanistic advance in liver biology or an AASLD-relevant clinical finding for a North-American/international readership.
The author is choosing between Hepatology (AASLD), Journal of Hepatology (EASL), and a general GI or general-medicine venue.
The author needs the journal's reporting-guideline, registration, and desk-reject expectations for hepatology.
Scope & topic fit
Cellular and molecular hepatobiliary biology: hepatocyte/cholangiocyte and stellate-cell biology, liver immunology, fibrogenesis, regeneration, and metabolism.
Metabolic and steatotic liver disease (MASLD/MASH) and alcohol-related liver disease — mechanisms, models, biomarkers, and trials.
Cirrhosis, portal hypertension, decompensation, and acute/acute-on-chronic liver failure — pathophysiology and outcomes.
Liver cancer (HCC, cholangiocarcinoma) tumor biology, microenvironment, and clinically anchored studies; autoimmune/cholestatic disease (AIH, PBC, PSC).
Liver transplantation biology and outcomes, including ischemia-reperfusion, rejection, and immunosuppression science.
Method & evidence bar
Basic/translational studies need rigorous controls, adequate biological replication, and validation across complementary models with disease relevance; single-cell-line claims are insufficient.
Clinical studies must be adequately powered with prespecified, clinically meaningful endpoints; surrogate/biomarker endpoints (fibrosis stage, viral markers) require validation and justification.
The applicable reporting guideline must be followed and its checklist supplied: CONSORT for trials, STROBE for observational studies, PRISMA for systematic reviews, STARD for diagnostic accuracy; ARRIVE-aligned animal-study reporting where relevant.
Interventional trials require prospective registration with the registration number and protocol/statistical-analysis plan.
Mechanistic claims must be supported by direct, manipulative evidence (gain/loss of function), not correlation alone; human-sample validation strengthens fit.
Observational and registry analyses must address confounding, selection, and competing risks; causal language must match the design.
Structure & house style
AASLD/Wiley format with a structured abstract; re-check current article types (Original Article, etc.), graphical-abstract requirements, and limits on the live guide.
The introduction frames a focused biological or clinical question and its significance; the discussion states the mechanistic interpretation and, where relevant, the clinical/guideline implication, using current AASLD nomenclature (MASLD/MASH).
Figures must include the controls, replication, and quantification supporting each mechanistic claim; CONSORT/STROBE/PRISMA flow diagrams are expected where applicable.
Supplements carry full methods, antibody/reagent and model details, the protocol, and extended analyses.
Combines search results from multiple sources into coherent, deduplicated answers with source attribution. Handles confidence scoring based on freshness and authority, and summarizes large result sets effectively.